Key result
Following the diagnosis and treatment of ischemic heart disease, the prevalence of metabolic syndrome increased from 71.0% to 80.4% (p < 0.001) due to the initiation of pharmacotherapy, despite significant reductions in elevated BMI, triglycerides, and systolic blood pressure.
Why the study?
Does the diagnosis and subsequent management of ischemic heart disease improve metabolic syndrome parameters in affected patients?
Observational (n=107)
No
Does the diagnosis and subsequent management of ischemic heart disease improve metabolic syndrome parameters in affected patients?
Absolute Event Rate: 80.4% vs 71%
p-value: p=<0.001
Following a diagnosis of ischemic heart disease, patients showed significant improvements in some metabolic syndrome parameters like BMI, triglycerides, and systolic blood pressure, though central obesity and fasting glucose worsened.
Post-IHD pharmacotherapy may increase metabolic syndrome prevalence; leaves open targeted mitigation strategies in prospective cohorts.
Introduction. Metabolic syndrome is a cluster of metabolic disorders that increase the risk of type 2 diabetes and cardiovascular diseases. The aim of the study is to determine the frequency of certain metabolic syndrome components by applying International Diabetes Federation (IDF) criteria prior to and after diagnosing ischemic heart disease. Methods. In a retrospective-prospective study, risk factors for metabolic syndrome prior to and after the ischemic heart disease were analyzed. The sample included 107 patients suffering from ischemic heart disease. All patients with ischemic heart disease treated in the Primary Healthcare Centre Laktaši (Bosnia and Herzegovina) from 1st January 2010 to 30th November 2015 were included in the study. The patients were diagnosed with the ischemic heart disease by cardiology examination, ergometric testing and coronagraphy. All patients were subjected to anthropometric and blood pressure measurement and their blood samples were taken after 12 hours of being famished in order to determine the glucose and lipid levels. Results. After cardiovascular event a statictically significant decrease in the number of patients with increased body mass index (46 vs. 38, p < 0.001), increased levels of triglycerides (53 vs. 37, p < 0.001), low levels of HDL cholesterol (31 vs. 30, p = 0.100), increased systolic blood pressure (77 vs. 23, p = 0.004) was registered. Statistically significant increase in the number of patients with central obesity (61 vs. 92, p < 0.001), increased fasting blood glucose (68 vs. 73, p < 0.001), as well as those receiving pharmacotherapy for hypertension (49 vs. 90, p = 0.002) and diabetes (14 vs. 24, p < 0.001) was recorded. Conclusion. After diagnosing ischemic heart disease, the majority of metabolic syndrome parameters were reduced by applying pharmacological and non-pharmacological measures. Family physicians have an important role in an early identification of patients with metabolic syndrome as well as in the prevention of ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Pećanac et al. (2018) conducted an observational in Ischemic heart disease (n=107). Diagnosis and treatment of ischemic heart disease vs. Baseline (prior to cardiovascular event) was evaluated on Metabolic syndrome diagnosis (IDF criteria) (p=<0.001). Following the diagnosis and treatment of ischemic heart disease, the prevalence of metabolic syndrome increased from 71.0% to 80.4% (p < 0.001) due to the initiation of pharmacotherapy, despite significant reductions in elevated BMI, triglycerides, and systolic blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: